Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pulmonary/Respiratory Diseases | Trauma/Emergency Medicine | Immunology/Infectious Diseases
Disease Category: COPD (Chronic Obstructive Pulmonary Disease)

Trial Information

A phase IIA, dose escalating study to evaluate the safety, tolerability and efficacy of BIO-11006, a nebulized investigational inhalation solution, versus placebo in subjects with COPD suffering from chronic bronchitis. BIO-11006 Inhalation Solution is an investigational therapeutic agent that is being tested for its ability to inhibit mucus secretion and to reduce inflammation.

This research trial will be conducted over the course of 2 months and will include 11 clinic visits. Study procedures include clinical lab work, physical examinations, EKGs, pulmonary function tests, lung volume testing, 6 minute walk tests and questionnaires.

Patient Inclusion Criteria
Eligible candidates must have a clinical diagnosis of COPD with chronic bronchitis. Patients should be 45 years of age or older and can be male or female. Current or former smokers with at least a 20 pack year history of smoking.

Patient Exclusion Criteria
Use of oxygen 6 weeks preceding the study and throughout. Change in smoking status in the previous 6 months. History of cancer other than basal cell carcinoma. Pregnancy. Any clinically significant history of heart, liver or lung disease other than COPD. Participants will also be deemed ineligible with unstable diabetes or hypertension.

Emerald Coast Research Associates
Located in:
Panama City, FL 32405

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.